| II-15 Matthias Frei Distinguishing myelosupressive response of a paclitaxel –radium-223 combination using a model-based analysis of an individual cross-over phase-Ib trial in cancer patients with bone lesions Wednesday 15:50-17:20 |
| II-15 Matthias Frei Distinguishing myelosupressive response of a paclitaxel –radium-223 combination using a model-based analysis of an individual cross-over phase-Ib trial in cancer patients with bone lesions Wednesday 15:50-17:20 |